Loading...

CC CHEMOURS CO Capital Structure Changes 8-K Filing

CHMR

CC

CHEMOURS CO

(CC)

2025 8-K

Land Sale Agreement

Q3 Financial Results

Severance Policy Approved

Financial Agreements Update

Board Appointments

Board Resignation

Financial Statements

Regulatory Compliance

Financial Statements

Agreement Amendment

Board Departure

Board Departure

Earnings Results

Board Appointment

Board Appointment

Credit Agreement Amendment

Credit Agreement Amendment

Q3 Earnings Report

Investor Presentation

Earnings Reports

Appointment of Controller a...

Appointment of Director

Appointment of CFO

Disruption of Operations

Annual Meeting of Shareholders

Earnings Reports

Resignation of Jonathan S. ...

Earnings Reports

Appointment of CEO

Financial Results

Management Changes

Appointment of Alister Cowa...

Departure of Director and A...

Rescheduling of Financial R...

Consent Judgment with State...

Management Changes

Earnings Reports

Entry into a Material Defin...

Sale of Glycolic Acid business

Closure of Manufacturing Si...

Settlement Agreement for PF...

Management Changes

Agreement to Resolve PFAS C...

Disposals and divestitures

Resignation of President

Earnings Reports

Annual Meeting of Shareholders

Amendment to Receivables Pu...

Management Changes

Resignation of President

Amendment to Credit Agreement

Earnings Reports

External Links:

On October 15, 2025, Chemours Co extended a $1.05 billion loan's maturity to 2032 and secured a €180 million receivables purchase agreement with BNP Paribas, critical for its cash flow management.

AI Assistant

CHEMOURS CO

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.